CA
NZ
UK
AU
IND
US
IRhythm Holdings, Inc. (NASDAQ: IRTC) has settled patent litigation with Baxter, agreeing to a payment of $50 million to resolve disputes related to patent infringements. This agreement comes on the heels of iRhythm's recent strong financial performance, including a second quarter revenue growth of …
Janux Therapeutics reported Q1 EPS of $‑0.39, outperforming the $‑0.54 consensus by $0.15. The narrower loss signals improving cost discipline and a cash cushion of $970.9 million, giving investors confidence in the firm’s ability to fund its prostate‑cancer pipeline.Key HighlightsEPS beat consensus, demonstrating cost‑growth …
This significant growth is driven primarily by a 12% increase in its domestic core business, alongside a remarkable 59% surge in international revenue. As the company continues to establish itself in competitive markets, this financial turnaround offers a positive outlook for investors, especially with …
LifeStance Health Group, Inc. (NASDAQ: LFST) achieved a significant milestone by reporting second-quarter revenue of $435.4 million, representing a 26% increase from $345.3 million in the same period last year. The earnings per share (EPS) came in at $0.06, surpassing analysts' expectations of $0.04. …
Lineage Cell Therapeutics (NYSE American: LCTX) disclosed second‑quarter results showing revenue of $1.1 million, representing a net decrease of $1.7 million compared with the same period last year. The company’s cash, cash equivalents and marketable securities totaled $50.8 million, a level that extends the …
The company also disclosed a net loss of $44.8 million, up $2.1 million from the same period a year earlier, while cash and marketable securities stood at $228.0 million. A strong manufacturing success rate of 97% for its dual‑targeting CAR‑T candidate ronde‑cel, coupled with …
Insulet Corporation has significantly revised its revenue outlook for 2026, now projecting growth between 20% and 22%. This downward adjustment stems from lower than expected retention and utilization rates among Type 2 diabetes patients, particularly during critical early therapy phases. The company's approach is …
American Healthcare REIT, Inc. achieved impressive quarterly results, reporting an earnings per share (EPS) of $0.54 for the quarter ended June 30, 2026. With annual market capitalization now at approximately $11.4 billion, this strong earnings announcement signals a vital growth trajectory for American Healthcare …
Arcutis Biotherapeutics has reported a strong second quarter for 2026, highlighting a 59% increase in revenue that signals significant market traction. This growth reflects heightened demand for the company's dermatological products amid an expanding pipeline. The achievement of profitability represents a critical milestone, affecting …
The company also signaled that disciplined cost control will enable cash‑flow breakeven in the fourth quarter, a milestone that could unlock greater financial flexibility and appeal to value‑focused investors.
Please wait processing your request...